Intellin: A smart platform to reduce the reoccurrence of diabetic foot ulcers

糖尿病足溃疡（DFUs）是一个主要的世界性问题，15%的糖尿病患者发生，其中56%的患者在首次发病后5年内死亡。复发率约为每年50%，目前的方法和治疗需要多学科评估（包括糖尿病专家、外科医生和足病医生）。目前在英国没有通用的方法来根据DFU复发的风险对患者进行分层。该联盟由Gendius（项目负责人，专注于移动医疗解决方案的初创企业）、索尔福德皇家医院（临床试验的开发和管理）和FIECON（健康经济学的发展）通过开发Intellin(一种使用“模糊逻辑”的人工智能解决方案，根据DFU风险因素对糖尿病患者进行分层（导致更具体和有效的干预），并根据输入的数据提供个性化的建议和提醒，共同利用这一重要的市场机会。如果将dfu的年复发率从50%降低到40%，将为英国医疗行业每年节省1亿英镑。如果成功，DFU特定应用程序将于2019年进入市场。

Diabetic Foot Ulcers (DFUs) are a major worldwide issue, occurring in 15% of diabetes sufferers and 56% of these patients die within 5 years of the first occurrence. The recurrence rate is approximately 50% per annum with current methods and treatment requiring a multidisciplinary assessment (including diabetes specialists, surgeons and podiatrists). There are currently no universal methods across the UK to stratify patients according to their risk of reoccurrence of a DFU. The consortium consisting of Gendius (Project leader, start-up specialising in MHealth Solutions), Salford Royal Hospital (development and management of clinical trial) and FIECON (development of health economics) have come together to exploit this significant market opportunity through the development of Intellin – an AI solution using ‘fuzzy logic’ to stratify diabetes patients based on DFU risk factors (leading to more specific and effective interventions) and offer personalised advice and reminders based on inputted data, leading to potential annual savings of £100M for the UK health industry, based on a reduction to the annual reoccurrence of DFUs from 50% to 40%.If successful, market entry for the DFU specific application will be in 2019.